Rice Jennifer, Philbin Nora, Light Rick, Arnaud Françoise, Steinbach Thomas, McGwin Gerry, Collier Sarah, Malkevich Nina, Moon-Massatt Paula, Rentko Virginia, Pearce L Bruce, Ahlers Stephen, McCarron Richard, Handrigan Michael, Freilich Daniel
Naval Medical Research Center, Silver Spring, Maryland, USA.
J Trauma. 2008 May;64(5):1240-57. doi: 10.1097/TA.0b013e318058245e.
Some hemoglobin-based oxygen carriers (HBOCs) improve outcome in animal models of hemorrhagic shock (HS) in comparison with standard asanguinous resuscitation fluids. Nevertheless, concern about intrinsic vasoactivity, linked in part to low-molecular weight (MW) hemoglobin (Hb), has slowed HBOC development. We assessed the impact of decreasing the low-MW Hb component of bovine HBOC on vasoactivity in severe HS.
Anesthetized invasively monitored swine were hemorrhaged 55% blood volume and resuscitated with bovine HBOC containing 31% (31 TD [HBOC-301]), 2% (2 TD [HBOC-201]), or 0.4% (0.4 TD) low-MW Hb. Pigs received four 10 mL/kg infusions over 60 minutes, hospital arrival was simulated at 75 minutes, organ blood flow (BF) was evaluated by microsphere injection, and monitoring was continued for 4 hours followed by complete necrotic evaluation.
There were few differences between 2 TD and 0.4 TD. Thirty-one TD pigs had higher systemic and pulmonary blood pressure (BP), systemic vascular resistance index, and pulmonary artery wedge pressure, compared with 2 TD or 0.4 TD (p < 0.01); however, pigs in all groups had at least mildly elevated BP. Transcutaneous tissue oxygenation, base excess, and mixed venous oxygen saturation were similar across groups; lactate and methemoglobin were highest with 0.4 TD (p < 0.03). There were no group differences in BF. Over time, myocardial BF increased and hepatic BF decreased in all groups (for 31 TD, p < 0.05); renal BF was unchanged in all groups. There were no group differences in heart, lung, or liver histopathology, and survival.
Although purification from 31% to 2% low-MW Hb content significantly decreased vasoactive responses, further purification to 0.4% had no additional clinically measurable effects in severe HS. If further diminution in HBOC vasoactivity is desired for use in HS, additional technical approaches may be required.
与标准无血复苏液相比,一些基于血红蛋白的氧载体(HBOCs)可改善失血性休克(HS)动物模型的预后。然而,对部分与低分子量(MW)血红蛋白(Hb)相关的内在血管活性的担忧减缓了HBOC的研发进程。我们评估了降低牛源性HBOC中低MW Hb成分对严重HS血管活性的影响。
对经侵入性监测的麻醉猪放血55%血容量,并用含31%(31 TD [HBOC-301])、2%(2 TD [HBOC-201])或0.4%(0.4 TD)低MW Hb的牛源性HBOC进行复苏。猪在60分钟内接受4次10 mL/kg的输注,模拟在75分钟时到达医院,通过微球注射评估器官血流(BF),并持续监测4小时,随后进行完全坏死评估。
2 TD和0.4 TD之间差异不大。与2 TD或0.4 TD相比,31 TD组猪的体循环和肺循环血压(BP)、体循环血管阻力指数和肺动脉楔压更高(p < 0.01);然而,所有组的猪血压至少有轻度升高。各组间经皮组织氧合、碱剩余和混合静脉血氧饱和度相似;乳酸和高铁血红蛋白在0.4 TD组最高(p < 0.03)。BF在各组间无差异。随着时间推移,所有组中心肌BF增加而肝BF减少(31 TD组,p < 0.05);所有组中肾BF无变化。各组在心脏、肺或肝脏组织病理学及生存率方面无差异。
尽管将低MW Hb含量从31%纯化至2%可显著降低血管活性反应,但在严重HS中进一步纯化至0.4%并无额外的临床可测量效应。如果希望在HS中进一步降低HBOC的血管活性,可能需要其他技术方法。